OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) shares were up 1% on Wednesday . The stock traded as high as $3.10 and last traded at $2.92. Approximately 181,705 shares traded hands during mid-day trading, an increase of 21% from the average daily volume of 149,960 shares. The stock had previously closed at $2.89.
Analysts Set New Price Targets
Separately, HC Wainwright reissued a "buy" rating and issued a $7.00 price objective on shares of OKYO Pharma in a research report on Monday, May 5th.
Get Our Latest Research Report on OKYO Pharma
OKYO Pharma Price Performance
The firm has a 50-day moving average of $2.11 and a 200 day moving average of $1.52.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of OKYO. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of OKYO Pharma in the second quarter valued at $28,000. FNY Investment Advisers LLC bought a new position in shares of OKYO Pharma during the 1st quarter valued at about $25,000. Finally, Dauntless Investment Group LLC bought a new position in shares of OKYO Pharma during the 1st quarter valued at about $2,526,000. 2.97% of the stock is owned by institutional investors.
OKYO Pharma Company Profile
(
Get Free Report)
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.
See Also
Before you consider OKYO Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OKYO Pharma wasn't on the list.
While OKYO Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
